Chronic kidney disease G5D Peritoneal dialysis patient with hypertension
Conditions
Interventions
Oral administration of sacubitril valsartan
Sponsors
Osano Keiichi
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patients who meet all of the following criteria will be included. 1. Adult patients, regardless of gender, who visit the Department of Nephrology at Yamanashi University Hospital and have been undergoing peritoneal dialysis for at least six months. 2. Peritoneal dialysis patients with hypertension. 3. Patients who can provide written informed consent to participate in this study. Consent must be given by the individual.
Exclusion criteria
Exclusion criteria: 1.Patients who meet the contraindications for sacubitril valsartan 2.Patients who were taking sacubitril valsartan before enrollment in the study 3.If a doctor determines that the person is unsuitable for the program
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in LVEF 3 and 6 months after taking Sacubitril Valsartan compared to before administration | — |
Contacts
Public ContactKeiichi Osano
University of Yamanashi Hospital
Outcome results
None listed